{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-291669","form_type":"8-K","ticker":null,"cik":"0001845337","company_name":"Day One Biopharmaceuticals, Inc.","filed_at":"2023-12-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.000179+00:00","generated_at":"2026-06-07T15:43:36.940758+00:00","sec_items":["5.05","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"confidence":"high","headline":"Day One Biopharma updates Code of Ethics; no waivers granted","bullets":["Amendments cover conflicts of interest, related party transactions, confidentiality, and reporting violations.","Added provisions on fair dealing and compliance with healthcare laws.","No explicit or implicit waivers resulted from the amendments.","Code applies to all officers, directors, and employees."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-291669","json":"https://secwatch.observer/filing/0001193125-23-291669.json","markdown":"https://secwatch.observer/filing/0001193125-23-291669.md","text":"https://secwatch.observer/filing/0001193125-23-291669.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1845337/000119312523291669/0001193125-23-291669-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1845337/000119312523291669/d636207d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T15:43:36.940758+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5c5372c553a6cbb154da2262521547766c9b4c25","claim":"Day One Biopharmaceuticals, Inc.: Amended Code of Business Conduct and Ethics to update policies on conflicts of interest, related party transactions, confidentiality, reporting violations, fair dealing, and healthcare law compliance (effective 2023-12-07).","evidence_excerpt":"On December 7, 2023, the Board of Directors (the “Board”) of Day One Biopharmaceuticals, Inc. (the “Company”) approved certain amendments to its Code of Business Conduct and Ethics","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1845337/000119312523291669/0001193125-23-291669-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"code of ethics"},{"label":"Effective","value":"2023-12-07"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}